Vifor Pharma

Vifor Pharma EPS

Delisted·Dec 22, 2022

The Earnings per Share (EPS) of Vifor Pharma (VIFN.SW) as of Nov 22, 2026 is 2.47 CHF. In the previous year, Earnings per Share (EPS) was 5.54 CHF — a change of -55.50% (lower).

EPS

2.47CHF

YoY

-55.50%

Last updated:

Earnings per Share (EPS) of Vifor Pharma is 2021 2.47 CHF. Earnings per Share (EPS) of Vifor Pharma was 2020 5.54 CHF. It decreases by -55.50% lower compared to the previous year.

The Vifor Pharma EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
2.45 CHF
Jan 1, 2020
5.54 CHF
Jan 1, 2021
2.47 CHF
Jan 1, 2022 (e)
3.63 CHF
Jan 1, 2023 (e)
4.24 CHF
Jan 1, 2024 (e)
5.03 CHF
Jan 1, 2025 (e)
8.99 CHF
Jan 1, 2026 (e)
10.68 CHF
The Vifor Pharma EPS history
YEAREPSYoY
est10.68CHF+18.78%
est8.99CHF+78.77%
est5.03CHF+18.60%
est4.24CHF+16.80%
est3.63CHF+47.13%
2.47CHF-55.50%
5.54CHF+126.16%
2.45CHF+4.65%
2.34CHF-86.72%
17.64CHF+370.14%
3.75CHF-19.14%
4.64CHF+5.90%
4.38CHF-3.99%
4.56CHF+16.90%
3.90CHF-0.82%
3.94CHF+10.04%
3.58CHF+10.76%
3.23CHF+10.74%
2.92CHF+40.96%
2.07CHF+30.15%
1.59CHF+29.50%
1.23CHF+24.88%
0.98CHF-4.05%
1.02CHF+12.59%
0.91CHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vifor Pharma stock

Earnings per Share (EPS) of Vifor Pharma is 2.47 CHF in 2021.

Earnings per Share (EPS) of Vifor Pharma changed from 5.54 CHF to 2.47 CHF, representing a -55.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vifor Pharma

All Key Metrics — Vifor Pharma